Blood
Articles in this Issue
Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs) are transformative immunother...
The dual-target molecular glue degrader INNO-235 effectively mediates the degradation of GSPT1 and CK1α, and exhibits potent anti-tumor activity in TP53 mutant burkitt lymphoma
Abstract Burkitt lymphoma (BL) is characterized by the translocation and dysregulation of the proto-oncogene MYC. Owing to its high aggressi...
Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease
Abstract Background: Chronic graft-versus-host disease (cGVHD) is a leading cause of non-relapse mortality following allogeneic hematopoieti...
Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma
Abstract Purpose/Objectives: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) thera...
Mezigdomide overcomes CRBN mutations emerging post IMiD therapy
Abstract Background: Cereblon (CRBN), a substrate receptor for the CRL4CRBN E3 ligase complex, is the molecular target of immunomodulatory a...
Evolving insights and changes in survival of erdheim-chester disease over time
Abstract Background:Erdheim-Chester Disease (ECD) is a rare, incurable histiocytic neoplasm. Since its recognition in 1930, our understandin...
Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement
Abstract Background and Significance: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, with a median age of 69 years at...
Real-world characteristics and treatment patterns in patients with essential thrombocythemia by thrombosis risk levels
Abstract Introduction: Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm characterized by elevated platelet counts from ab...
Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia
Abstract Background: FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is one of the most frequent mutations in acute myeloi...
Clonal hematopoiesis in t-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution
Abstract T-follicular helper cell lymphomas (TFHL) are frequently associated with epigenetic mutations and clonal hematopoiesis (CH), but th...
Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix
Abstract Car T therapy improved the prognosis of relapse/refractory lymphoma patients, but managing toxicities and progressions remains chal...
PKM2 modulation regulates leukemia cell survival.
Abstract Acute myeloid leukemia (AML) is characterized by an aberrant metabolic phenotype in which cells rely on aerobic glycolysis (AG) to...
Anti-CD7 CAR-T cells in patients with relapsed or refractory CD7+ Acute Myeloid Leukemia: First-in-human phase I study
Abstract Background The prognosis for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remains poor, highlighting an urgen...
Mechanism for HSPC expansion in the endothelial cuddling niche microenvironment through inflammatory lipid mediators receptor CysLTR1
Abstract Hematopoietic stem and progenitor cells (HSPCs) closely interact with the niche, allowing dynamic regulation of hematopoiesis. Desp...
A randomized study of ropeginterferon in combination with bosutinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic Phase. the bosupeg trial from the Nordic CML study group
Abstract Introduction: Prior studies combining pegylated interferon-α to Imatinib and Nilotinib in newly diagnosed CML patients have indicate...
Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial
Abstract Introduction: Chemotherapy-free, bispecific antibody (BsAb)-containing therapies have the potential to challenge the role of standa...
Therapeutic drug monitoring-guided individualized dosing of multiple BTK inhibitors combined with voriconazole: Real-world evidence on managing drug-drug interactions
Abstract Introduction: Bruton's tyrosine kinase inhibitors (BTKis) have transformed the treatment landscape of B-cell malignancies, demonstr...
Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma
Abstract Background: A prior analysis of mosunetuzumab (Mosun) SC, a CD20xCD3 T-cell-engaging bispecific antibody, with polatuzumab vedotin...
Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes
Abstract Introduction Genomic analysis of multiple myeloma has advanced greatly in recent years, but traditional short-read sequencing has li...
Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation
Abstract Introduction Ivosidenib (IVO) is approved as monotherapy and in combination with azacitidine for frontline treatment of patients (p...
Impact of RAS mutations on outcomes in newly diagnosed AML patients
Abstract Introduction: Mutations in RAS oncogenes (NRAS and KRAS) are present in 15–20% of patients (pts) with acute myeloid leukemia (AML)....
Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease
Abstract Objective Neurocognitive complications in pediatric sickle cell disease (SCD)—even without overt stroke—are inc...
A diagnostic pivot: Paroxysmal nocturnal hemoglobinuria mimicking refractory immune thrombocytopenia in an elderly woman with autoimmune comorbidities
Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder characterized b...
Genomic and transcriptomic characterization of acute myeloid leukemia with CD123 overexpression
Abstract CD123, the interleukin-3 receptor α chain (encoded by IL3RA), is closely linked to the maintenance of myeloid progenitors. In acute...
Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma
Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, with approximately 25,000 new cases diagnosed annual...